Richard Miller Awarded 2020 Drug Hunter Award by UC Drug Discovery Consortium
The Drug Hunter Award recognizes individuals that have made a significant impact in the drug development space, contributing to bringing new breakthrough drugs to market. Prior award winners include
Dr. Miller has over 25 years of experience developing successful medicines. Most notably, he played an instrumental role in developing and bringing to market both Rituxan and Imbruvica: highly successful and multi-billion dollar medicines. Rituxan was the first
Dr. Miller was co-founder and chief executive officer of Pharmacyclics, where he led the initial discovery and development efforts for Imbruvica. Prior to that, he was a co-founder, Vice President and Director of
Following his acceptance of the Drug Hunter Award, Dr. Miller delivered a presentation giving insight into his impressive career dedicated to lymphoma research and drug development. “I have had the good fortune to study one disease really carefully, read all about it, see patients with it and really be totally immersed in it for over 30 years now. That has given me perspective and advantage in doing this kind of work,” said Dr. Miller. A recording of Dr. Miller’s presentation can be found here.
About
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These product candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and in combination with pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Chief Financial Officer
650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT:
W2O pure
+1 213-262-9390
sseapy@purecommunications.com
Source: Corvus Pharmaceuticals, Inc.